The Ministry of Food and Drug Safety has granted domestic product approval for Chong Kun Dang’s type 2 diabetes treatment, Dubiempol Sustained Release Tablet.
Chong Kun Dang announced on Wednesday that through a public disclosure that it had secured domestic product approval for the drug on Tuesday. This approval comes approximately one year after the company submitted its application in April of last year.
This medication is intended for adult patients with type 2 diabetes who are suitable for combination therapy with lobeglitazone, empagliflozin, and metformin.
Chong Kun Dang expects that this fixed-dose combination of lobeglitazone, empagliflozin, and metformin will offer a new treatment option for type 2 diabetes patients whose blood sugar levels are not adequately controlled with the combination of empagliflozin and metformin. The company believes this will also improve medication adherence.
With the approval from the Ministry of Food and Drug Safety, Chong Kun Dang plans to launch the product in the domestic market within this year.